BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24996439)

  • 41. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
    Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
    Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glycomic alterations are associated with multidrug resistance in human leukemia.
    Zhang Z; Zhao Y; Jiang L; Miao X; Zhou H; Jia L
    Int J Biochem Cell Biol; 2012 Aug; 44(8):1244-53. PubMed ID: 22579717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impairment of homologous recombination control in a Fanconi anemia-like Chinese hamster cell mutant.
    Larminat F; Germanier M; Papouli E; Defais M
    Biol Cell; 2004 Sep; 96(7):545-52. PubMed ID: 15380621
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Goldenberg GJ; Wang H; Blair GW
    Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
    Stecklein SR; Jensen RA
    Transl Res; 2012 Sep; 160(3):178-97. PubMed ID: 22683426
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
    Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
    Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
    Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
    Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chaetominine reduces MRP1-mediated drug resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells.
    Yao J; Wei X; Lu Y
    Biochem Biophys Res Commun; 2016 May; 473(4):867-873. PubMed ID: 27038543
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in protein expression due to deleterious mutations in the FA/BRCA pathway.
    Salles D; Cabral RE; Pizzatti L; Bisch PM; Paixão JC; de Almeida CE; Seuánez HN; Cabral-Neto JB
    Biochem Biophys Res Commun; 2007 Dec; 364(4):755-60. PubMed ID: 17977515
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
    Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
    Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells.
    Chen P; Li J; Chen YC; Qian H; Chen YJ; Su JY; Wu M; Lan T
    Cell Oncol (Dordr); 2016 Dec; 39(6):511-522. PubMed ID: 27473273
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Antiproliferative effect of curcumin combined with cyclophosmide on the growth of human lymphoma cell line HT/CTX with drug resistance and its relation with FA/BRCA pathway].
    Xiao H; Zhang KJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):804-8. PubMed ID: 18718065
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
    Villamar Cruz O; Prudnikova TY; Araiza-Olivera D; Perez-Plasencia C; Johnson N; Bernhardy AJ; Slifker M; Renner C; Chernoff J; Arias-Romero LE
    Oncotarget; 2016 Nov; 7(47):76590-76603. PubMed ID: 27740936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modifications of oxido-reductase activities in adriamycin-resistant leukaemia K562 cells.
    Denis-Gay M; Petit JM; Mazat JP; Ratinaud MH
    Biochem Pharmacol; 1998 Aug; 56(4):451-7. PubMed ID: 9763220
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Downregulated miR‑130a enhances the sensitivity of acute myeloid leukemia cells to Adriamycin.
    Liu H; Liu M; Zhang J; Liang Y
    Mol Med Rep; 2020 Oct; 22(4):2810-2816. PubMed ID: 32945422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
    Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
    Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MERIT40 cooperates with BRCA2 to resolve DNA interstrand cross-links.
    Jiang Q; Paramasivam M; Aressy B; Wu J; Bellani M; Tong W; Seidman MM; Greenberg RA
    Genes Dev; 2015 Sep; 29(18):1955-68. PubMed ID: 26338419
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Folic acid supplementation in vitro induces cell type-specific changes in BRCA1 and BRCA 2 mRNA expression, but does not alter DNA methylation of their promoters or DNA repair.
    Price RJ; Lillycrop KA; Burdge GC
    Nutr Res; 2015 Jun; 35(6):532-44. PubMed ID: 25960189
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fanconi anemia pathway--the way of DNA interstrand cross-link repair.
    Yao CJ; Du W; Zhang Q; Zhang F; Zeng F; Chen FP
    Pharmazie; 2013 Jan; 68(1):5-11. PubMed ID: 23444773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MicroRNA-103 confers the resistance to long-treatment of adriamycin to human leukemia cells by regulation of COP1.
    Wan L; Tian Y; Zhang R; Peng Z; Sun J; Zhang W
    J Cell Biochem; 2018 May; 119(5):3843-3852. PubMed ID: 29058777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.